GSK cuts 1,200 jobs in Belgium, invests $800 million more in the U.S.—can Europe hold on?

On October 14, GlaxoSmithKline (GSK) notified Belgian trade unions of its plan to eliminate up to 1,217 local positions across multiple sites; factory workers are temporarily unaffected. Just two days earlier, GSK had announced an additional investment of over $800 million to expand its R&D and manufacturing facility in Pennsylvania, USA. One hand contracts in Europe while the other doubles down in the U.S.—same company, same week, opposite directions. Compiling this information isn’t easy—please consider liking and following! Is this an isolated case—or a trend? GSK is no outlier. This month, European pharmaceutical companies have taken unusually密集 actions: October 2: Bayer announced a $2.2 billion investment to build a new pharmaceutical production facility in Ohio; the first module is scheduled to come online in 2031. Though publicly denying concerns about tariffs, Bayer’s body speaks louder: $2.2 billion to build in the U.S. October 5: AstraZeneca inaugurated its new Global Strategic R&D Center in Kendall Square, Massachusetts. This single project exceeds $1 billion in investment, with local staff set to grow by over 50%—part of its broader $50 billion U.S. investment plan. AstraZeneca’s CEO, Pascal Soriot: “Post-2030 growth won’t rely on M&A.” Add GSK’s 1,200 job cuts in Belgium, and the map of European pharma is being redrawn. This isn’t relocation—it’s risk avoidance. The immediate trigger is tariffs. In April 2026, the U.S. signed an executive order imposing a 100% tariff on patented drugs and their active pharmaceutical ingredients (APIs), effective for different companies at the end of July and September respectively. Having a U.S. plant bypasses the tariff; lacking one doubles import costs. For patent-drug businesses already squeezed on margins, that choice is straightforward. Tariffs are merely the fuse. As early as April 2025, CEOs of the European Federation of Pharmaceutical Industries and Associations (EFPIA) confronted Ursula von der Leyen directly: on capital expenditure, intellectual property protection, regulatory approval speed, and innovation returns—U.S. leads Europe on every investment metric. They warned that without policy reform, R&D and manufacturing would continue shifting stateside. EFPIA estimated that of Europe’s planned €164.8 billion in investments between 2025 and 2029, roughly half of R&D spending and 85% of capital expenditure faced outward migration risks. A year and a half later, those warnings have materialized into groundbreaking ceremonies—and layoff notices. What is Europe losing? Note the details of Bayer’s new plant: APIs and finished dosage forms co-located in one campus, integrated with digital and automated technologies—anchored in future therapeutic areas like oncology, cardiovascular disease, and nephrology.

200,000 companies go bankrupt across Europe annually—from crisis to the next crisis

"From one crisis to the next"—as reported by Germany’s Der Spiegel on November 11, the latest study from German credit agency Creditreform reveals that during the pandemic, EU companies were frequently shielded from bankruptcy. Now, corporate bankruptcies are surging, reaching a total of 200,000 enterprises. Austria, the UK, and France saw the sharpest increases in company failures. In 2022, nearly 140,000 companies went bankrupt across 14 Western European EU countries, plus Norway, Switzerland, and the UK—a 24.2% increase year-on-year. Austria recorded the largest rise: +59.7% compared to the previous year. Next came the UK (+55.9%), France (+50%), and Belgium (+41.7%). Bankruptcies also rose in Switzerland, Ireland, the Netherlands, Spain, Norway, Finland, Sweden, and Germany. Even traditionally stable Germany saw a 3.8% uptick in bankruptcies, reaching 14,660 cases. By contrast, bankruptcies declined in Denmark, Luxembourg, Portugal, Italy, and Greece. In Eastern European EU countries, corporate bankruptcies surged by 53.5%, totaling over 60,000 cases. Among the 12 surveyed countries, seven registered increases—with Hungary, Bulgaria, and Lithuania reporting the steepest rises. Retail sector bankruptcies were especially high; hotel industry failures rose by 34.5%. Construction followed, up 24.7%. Service-sector bankruptcies climbed by one-fifth; manufacturing rose by 13.1%. Patrick Hantsch, Head of Economic Research at Creditreform, noted that after pandemic controls eased, Europe briefly experienced economic recovery—only to be derailed again by the war in Ukraine. The ensuing energy crisis struck Europe’s economy unprepared and hard. Many financially fragile firms could not withstand successive shocks. Over the past year, numerous companies struggled to cover soaring energy and raw-material costs amid rising interest rates—while many consumers curbed spending due to inflation. Austria’s Der Standard analyzed that European businesses are now feeling mounting economic pressure: high inflation, energy shortages, and macroeconomic instability have significantly increased insolvencies. During the two pandemic years, bankruptcy numbers were correspondingly low.

Vynova Belgium files for bankruptcy after rescue talks collapse

just now

Vynova Belgium filed for bankruptcy after failed recapitalization efforts amid soaring energy costs and weak demand. The closure adds to a wave of European chlor-alkali and vinyls plant shutdowns affecting major producers like Westlake and Dow.

chemweek

Vynova Belgium files for bankruptcy after rescue talks collapse

chemweek

2026-11-11

Vynova Belgium files for bankruptcy after rescue talks collapse

Vynova Belgium files for bankruptcy after rescue talks collapse

FAQ